ACS chemical neuroscience molecule spotlight on lorcaserin

Corey R. Hopkins

doi:10.1021/cn100059u

ACS chemical neuroscience molecule spotlight on lorcaserin

Corey R. Hopkins

Research output: Contribution to journal › Short survey › peer-review

4 Scopus citations

Abstract

Lorcaserin (APD-356) is the first in a new class of selective serotonin 5-hydroxytryptamine_2C (5-HT_2C) receptor agonists. On December 22, 2009, the compound's developer (Arena Pharmaceuticals) submitted an NDA to the FDA for approval for weight management.

Original language	English (US)
Pages (from-to)	718-719
Number of pages	2
Journal	ACS Chemical Neuroscience
Volume	1
Issue number	11
DOIs	https://doi.org/10.1021/cn100059u
State	Published - Nov 17 2010
Externally published	Yes

ASJC Scopus subject areas

Biochemistry
Physiology
Cognitive Neuroscience
Cell Biology

Access to Document

10.1021/cn100059u

Cite this

@article{276ff1d6259e4a44b38f23a0ac717744,

title = "ACS chemical neuroscience molecule spotlight on lorcaserin",

abstract = "Lorcaserin (APD-356) is the first in a new class of selective serotonin 5-hydroxytryptamine2C (5-HT2C) receptor agonists. On December 22, 2009, the compound's developer (Arena Pharmaceuticals) submitted an NDA to the FDA for approval for weight management.",

author = "Hopkins, {Corey R.}",

year = "2010",

month = nov,

day = "17",

doi = "10.1021/cn100059u",

language = "English (US)",

volume = "1",

pages = "718--719",

journal = "ACS Chemical Neuroscience",

issn = "1948-7193",

publisher = "American Chemical Society",

number = "11",

}

TY - JOUR

T1 - ACS chemical neuroscience molecule spotlight on lorcaserin

AU - Hopkins, Corey R.

PY - 2010/11/17

Y1 - 2010/11/17

N2 - Lorcaserin (APD-356) is the first in a new class of selective serotonin 5-hydroxytryptamine2C (5-HT2C) receptor agonists. On December 22, 2009, the compound's developer (Arena Pharmaceuticals) submitted an NDA to the FDA for approval for weight management.

AB - Lorcaserin (APD-356) is the first in a new class of selective serotonin 5-hydroxytryptamine2C (5-HT2C) receptor agonists. On December 22, 2009, the compound's developer (Arena Pharmaceuticals) submitted an NDA to the FDA for approval for weight management.

UR - http://www.scopus.com/inward/record.url?scp=78649477506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649477506&partnerID=8YFLogxK

U2 - 10.1021/cn100059u

DO - 10.1021/cn100059u

M3 - Short survey

C2 - 22778808

AN - SCOPUS:78649477506

SN - 1948-7193

VL - 1

SP - 718

EP - 719

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

IS - 11

ER -

ACS chemical neuroscience molecule spotlight on lorcaserin

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this